Menu Search
Equities

Akero Therapeutics Inc

0K4:FRA

Akero Therapeutics Inc

Actions
  • Price (EUR)29.62
  • Today's Change0.79 / 2.74%
  • Shares traded645.00
  • 1 Year change+101.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.

  • Revenue in USD (TTM)0.00
  • Net income in USD-237.22m
  • Incorporated2017
  • Employees60.00
  • Location
    Akero Therapeutics Inc601 Gateway Boulevard, Suite 350SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 487-6488
  • Fax+1 (302) 655-5049
  • Websitehttps://akerotx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.